September 22, 2017 05:11 PM EDT
Pharma

Al­ler­gan caps a bad day with news the FDA has kicked back a sup­ple­men­tal ap­pli­ca­tion for cariprazine

John Carroll

Editor & Founder

Al­ler­gan $AGN is not hav­ing a good day to­day.

Af­ter post­ing some mixed, weak ex­tend­ed year-two da­ta on its NASH drug, the com­pa­ny end­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times